First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Royalty Pharma plc

    RPRX · 3 developments mapped · last assessed 2026-09-05

    Market Ontology has mapped 3 macro, policy, and market developments to Royalty Pharma plc since 2026-09-05. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for RPRX yet, so no modelled value is shown. The RPRX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run RPRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for RPRX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint

      Loss of potential future royalty income from pelacarsen, offset by expected capital recovery.

      · Moves future royalty streams, investment return expectations

    What changed, by assumption

    Future royalty streams
    • 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
    Future royalty income streams
    • 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
    • 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-05Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-08-05Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-08-05Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-05Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-05RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpointmixed1-3m0.40
    2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500Mmixed1-3m0.40
    2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpointmixed1-3m0.60